Metis TechBio's 185% debut jump shows public investors are still willing to pay up for AI in healthcare, even when the business is young and still loss-making.
Metis TechBio landed in Hong Kong with the kind of first-day move that tells you where capital is hunting next. The company priced its H shares at HK$10.50, raised about HK$2.1 billion, or $270 million, and then watched the stock climb as high as HK$29.98 in early trading on May 13.
That is not just a strong biotechnology debut. It is a market signal. Investors are no longer looking only at large-language-model companies when they think about artificial intelligence. They are also looking at businesses that claim AI can change the slower, more expensive parts of drug development.
According to Bloomberg reporting carried by China Daily, Metis surged as much as 185% in its Hong Kong debut, while Impact Therapeutics, another biotech listing on the same day, rose as much as 82%. That matters because Hong Kong's IPO market has already been leaning into AI supply-chain stories this year, and now biotech is being pulled into the same current.
Metis was founded in 2020 and focuses on AI-assisted nanomaterial drug delivery and formulation. That sounds technical, but the commercial idea is simple enough. If a company can design better delivery systems for drugs, particularly RNA therapies and other complex payloads, it can improve how medicines reach the right part of the body and reduce some of the waste that slows development.
The company's platforms include NanoForge, AiLNP, AiRNA and AiTEM. Metis says these systems combine artificial intelligence, molecular simulation, quantum chemistry and lab testing to design and optimize lipids and formulations. Its own materials describe a library of more than 10 million ionizable LNP lipids, which is exactly the kind of platform claim public-market investors now understand quickly.
There is a reason that story travels well. The market has spent the past few years hearing that AI can write text, code and images. In healthcare, the promise is different. It is about shortening trial-and-error cycles, improving target selection, refining formulations and making expensive research work a little less blindly. That is more difficult to prove than a chatbot demo, but the upside is also more durable if the technology works.
Still, Metis is not being valued like a mature pharmaceutical company. It reported RMB105 million in 2025 revenue, up sharply from a small base, but remained loss-making. Market reports and IPO materials put its 2025 net loss at roughly RMB392 million. That gap is important. Investors are buying future productivity, licensing potential and platform scarcity, not current earnings.
The scarcity premium is real
Scarcity is doing a lot of work here. Hong Kong has several biotech names, but pure AI-biotech listings are still limited. Insilico Medicine, which listed in Hong Kong in late December 2025, raised about HK$2.28 billion and became a useful comparison point almost immediately. Its shares have climbed strongly since debut, giving investors a public example of how much demand there can be for AI drug-development exposure.
Metis also arrived with a serious cornerstone lineup. BlackRock, UBS, Mirae Asset Capital and ORIX were among the investors tied to the deal, while earlier reports put total cornerstone demand at about $148 million. That does not eliminate execution risk, but it gives the market comfort that large institutions were willing to underwrite the story before the first trade.
The use of proceeds also shows how broad Metis wants the platform to become. The company has earmarked funds for research and development, clinical trials, animal health and longevity applications. That breadth can help a young company find more ways to monetize its technology, but it can also become a discipline test. Public investors may enjoy the big vision on day one. Over time, they will want clearer proof of which parts can produce repeatable revenue.
That is where the comparison with Insilico becomes useful. Insilico has built its public story around AI-powered drug discovery and a pipeline of candidates, including licensing deals that help show external validation. Metis is more focused on delivery and formulation, a less glamorous but potentially crucial layer of the drug-development process. If AI can make better delivery systems faster, the value may sit close to the bottleneck that many drug developers already understand.
The next wave will test whether this is a durable rerating or just a hot window. Earendil Labs has been reported as a possible Hong Kong listing candidate that could raise as much as $500 million, and every successful debut makes the next issuer more tempted to come forward. That can deepen the market, but it can also crowd it quickly.
For now, Metis has given Hong Kong investors a sharper AI story than another model company chasing the same enterprise customers. It is a bet that artificial intelligence can reshape physical science, not just software. The first-day pop proves demand. The harder part begins now: turning an exciting platform into clinical progress, partner revenue and results that can survive after the IPO heat fades.
Also read: Anduril's $5 billion raise turns defense AI into venture's new prize • China's dark factory shows AI has entered the real production race • Meta workers turn AI training data into a workplace fight
